Cancer Biomarkers Market Worth $33.7 Billion By 2025 | CAGR: 14.3%: Grand View Research, Inc.
SAN FRANCISCO, June 21, 2017 /PRNewswire/ --
The global cancer biomarkers market [http://www.grandviewresearch.com/industry-analysis/cancer-biomarker-market ] is expected to reach a value of USD 33.7 billion by 2025, based on a new report by Grand View Research, Inc. Growing initiatives for development of drugs targeting novel cancer biomarkers coupled with the introduction of technologically advanced companion diagnostic kits is estimated to provide the market with high growth potential. Increasing awareness about personalized medicines amongst patients is further anticipated to boost adoption of cancer biomarkers.
(Logo: http://photos.prnewswire.com/prnh/20160524/371361LOGO )
In addition, presence of favorable government initiatives for the development of novel cancer diagnostic techniques is a key factor for market growth. For instance, the National Cancer Institute (NCI) provides funding to more than 8 research areas pertaining to cancer biomarker development. Cancer Research UK, Lung Cancer Research Foundation, and National Institutes of Health are some of the organizations providing funding for biomarker research.
People with high alcohol consumption, tobacco usage, unhealthy food habits, and sedentary lifestyle are reported to be 80% more at risk of developing cancer as compared to other individuals. Infections such as Human papillomavirus (HPV), Epstein-Barr virus, Hepatitis B virus, and Helicobacter pylori are also been studied to be related in cancer development.
Browse full research report with TOC on "Cancer Biomarker Market Analysis By Type (Breast, Prostate, Colorectal, Cervical, Liver, Lung Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, And Segment Forecasts, 2014 - 2025" at: http://www.grandviewresearch.com/industry-analysis/cancer-biomarker-market
Further key findings from the report suggest:
- Breast cancer was the largest segment by revenue share in 2016 owing to high
prevalence of this type of cancer
- Lung cancer is estimated to be the fastest-growing type due to increasing research
activities toward development of novel lung cancer biomarkers
- Genetic biomarkers, being the highest used and easily detectable held the majority
share of cancer biomarker market by biomolecule in 2016
- However, epigenetic biomarkers are anticipated to witness lucrative growth due to
increasing focus on finding the role of epigenetic modifications in cancer development
- Cancer biomarkers are majorly used for diagnostic purpose owing to their high
specificity
- The personalized medicine segment is estimated to witness fastest CAGR of 15.0% over
the forecast period
- North America dominated in terms of revenue share in 2016 due to established R&D
infrastructure and high acceptance of biomarker-based cancer testing in this region
- Asia Pacific is anticipated to grow at a substantial growth rate till 2025 with CAGR
of over 16.7%
- Some of the major companies in the cancer biomarkers market are Abbott Laboratories;
F.Hoffmann-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific Inc.; Affymetrix Inc.;
Illumina, Inc.; Agilent Technologies; Merck & Co. Inc.; Hologic, Inc.; Sino Biological
Inc.; and Becton, Dickinson and Company
Browse related reports by Grand View Research:
- Expression Vectors Market -
http://www.grandviewresearch.com/industry-analysis/expression-vectors-market
- Pre-packed Chromatography Columns Market -
http://www.grandviewresearch.com/industry-analysis/pre-packed-chromatography-columns-market
- Biomaterials Market -
http://www.grandviewresearch.com/industry-analysis/biomaterials-industry
- Biological Seed Treatment Market -
http://www.grandviewresearch.com/industry-analysis/biological-seed-treatment-market
Grand View Research has segmented the cancer biomarkers market by type, biomolecule, applications, and region:
- Cancer Biomarker Type Outlook (Revenue, USD Billion, 2014 - 2025)
- Breast cancer
- Prostate cancer
- Colorectal cancer
- Cervical cancer
- Liver cancer
- Lung cancer
- Others
- Cancer Biomarker Biomolecule Outlook (Revenue, USD Billion, 2014 - 2025)
- Genetic Biomarkers
- Epigenetic Biomarkers
- Metabolic Biomarkers
- Proteomic Biomarkers
- Others
- Cancer Biomarker Application Outlook (Revenue, USD Billion, 2014 - 2025)
- Drug discovery and Development
- Diagnostics
- Personalized medicine
- Others
- Cancer Biomarker Regional Outlook (Revenue, USD Billion, 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- China
- Japan
- Latin America
- Mexico
- Brazil
- MEA
- South Africa
Read Our Blog: Cancer Biomarkers Market: Increasing demand for rapid and specific cancer diagnosis [http://www.grandviewresearch.com/blog/cancer-biomarker-market-insight-size-share ]
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: +1-888-202-9519
Email: sales@grandviewresearch.com
Web: http://www.grandviewresearch.com
Photo:
http://photos.prnewswire.com/prnh/20160524/371361LOGO
SOURCE Grand View Research, Inc.
